Submitted by Anonymous (not verified) on 5 July 2024 - 14:40
Opinion/decision on a Paediatric investigation plan (PIP): Adtralza, Tralokinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0186/2023
Source: